ClinicalTrials.gg
Not yet recruitingNCT07842159LAVAUpdated Sep 25, 2026

Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy

A Phase 1/2 interventional study of Combined Bupivacaine and Exparel and Normal Saline (NS) in Pain, Postoperative, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by The University of Texas Health Science Center, Houston · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston — 1 open to participants now, 1 under way, none of them phase 3. Pain, Postoperative · The University of Texas Health Science Center, Houston.

Planned enrollment
5th of 16
104 · median 55
Started
2026
the only one that year
Phase 1/2
Only one
of the 18
Registered
18th of 18
by date

Among the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1/2, and was the 18th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

1 of the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

The purpose of this study is to compare recovery unit and post operation day (POD) 1 pain score in women following elective robotic assisted TLH (RA-TLH) for benign indication with and without local vaginal cuff injection of short acting bupivacaine and long acting Exparel, to evaluate postoperative pain management and control by assessing the amount and frequency of NSAIDS and opioids taken and to assess bleeding, vaginal discharge and or vaginal dehiscence at the postoperative follow up visit.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • elective Robotic assisted (RA) Total Laparoscopic Hysterectomy (TLH)
  • Total Laparoscopic Hysterectomy (TLH)
  • Benign
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 66.5kg weight
  • elective Robotic assisted (RA) Total Laparoscopic Hysterectomy (TLH) for benign indications at Memorial Hermann Hospital Texas Medical Center, Memorial Hermann Hospital Cypress and Memorial Hermann Hospital Greater Heights.

Exclusion criteria

Exclusion Criteria:

  • Combined operation or alternative approach
  • inpatient overnight admission
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Combined Bupivacaine and Exparel

    Drug: Combined Bupivacaine and Exparel

  • Placebo comparator
    Control

    Drug: Normal Saline (NS)

Interventions

  • DrugCombined Bupivacaine and Exparel

    In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will receive 20 cc of a mixture of 40 cc of short term 0.25% bupivacaine hydrochloride and long term 20 mL of Exparel® (266 mg/20 mL) mixed with 100cc of normal saline (total amount 160 cc) to the vaginal cuff using William's cystoscopy needle. The mixture will be infiltrated evenly at the uterosacral ligament with care (10 cc on each uterosacral ligament) taken to distribute the injection across the full length of the cuff at the end of the procedure.

  • DrugNormal Saline (NS)

    In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will get will get vaginal cuff infiltration with 20 cc of injectable NS at the end of the procedure.

06

What researchers measure

Primary outcomes

  1. Change in pain as assessed by the visual analog scale (VAS)

    Pain will be scored from 1-10 , higher number indicating more pain

    Time frame: 4-6 hours post operation, postoperative day 1, postoperative day 3

Secondary outcomes

  1. Change in level of pain control achieved as assessed by the amount of nonsteroidal anti-inflammatory drugs (NSAIDs) needed

    Time frame: 2-week and 6- week follow up

  2. Change in level of pain control achieved as assessed by the frequency of NSAIDS needed

    Time frame: 2-week and 6- week follow up

  3. Change in level of pain control achieved as assessed by the amount of opioids needed

    Time frame: 2-week and 6- week follow up

  4. Change in level of pain control achieved as assessed by the frequency of opioids needed

    Time frame: 2-week and 6- week follow up

  5. Change in level of bleeding as assessed by the volume of blood loss reported by the surgeon

    Time frame: 2-week and 6- week follow up

  6. Change in presence of vaginal dehiscence

    This will be categorically reported as a yes or no answer

    Time frame: 2-week and 6- week follow up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 25, 2026
StartEst.
Sep 17, 2026
Primary completionEst.
Mar 17, 2028
CompletionEst.
Sep 15, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842159
Responsible party
Asha Bhalwal (Associate Professor Non-Tenure Clinical, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 17, 2026 (estimated)
Primary completion
Mar 17, 2028 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Asha B Bhalwal, MD
Contact
Asha.B.Bhalwal@uth.tmc.edu
(713) 566-4605
Aya Sasson Mohr
Contact
Aya.MohrSasson@uth.tmc.edu
(713) 500-6412
Asha B Bhalwal, MD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion